Equity Details
Price & Market Data
Price: $0.193
Daily Change: +$0.125 / 64.67%
Daily Range: $0.0683 - $0.193
Market Cap: $197,674,683
Daily Volume: 5,000
Performance Metrics
1 Week: 9.21%
1 Month: 9.21%
3 Months: 9.15%
6 Months: 94.66%
1 Year: 210.3%
YTD: 182.6%
About Pacific Edge Limited (PFGTF)
Latest market trends for Pacific Edge Limited (PFGTF). The stock is priced at 0.193, showing a daily shift of +$0.125 / 64.67%. Market cap: 197,674,683. All performance data is provided for your review.
Details
Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a low risk of recurrence. In addition, the company is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.